Hypoparathyroidism: etiology, clinical manifestation, current diagnostics and treatment

Cover Page


Cite item

Full Text

Abstract

Parathyroid hormone (PTH) is the main regulator of calcium and phosphorus metabolism. PTH deficiency or tissue resistance to its effects results in hypoparathyroidism characterized by low serum calcium and elevated serum phosphate levels. The most common is post-operative hypoparathyroidism caused by an inadvertent damage or removal of the parathyroid glands, deterioration of blood supply to the neck region, most often during thyroid surgery. The second common form of the disease is the autoimmune one related with immune destruction of parathyroid cells. Less frequent causes of hypoparathyroidism include a variety of genetic syndromes, mitochondrial genome defects, and hypomagnesemia. The main signs and symptoms of hypoparathyroidism are related to hypocalcaemia and hyperphosphatemia land result in increased neuromuscular irritability and general autonomic reactivity, with finger and toe tingling, muscle cramps, tonic seizures, laryngo- and bronchospasm, and neurosis. These symptoms are closely associated with serum calcium levels; their severity depends on the degree of hypocalcaemia. Laboratory parameters confirming the diagnosis of hypoparathyroidism are hypocalcaemia, hyperphosphatemia, and reduced serum PTH. Treatment of hypoparathyroidism involves management of hypocalcaemic crisis and maintenance therapy. Acute hypocalcaemia, a  potentially life-threatening condition, is treated as an emergency with intravenous calcium combined with oral calcium and active vitamin D. Standard chronic treatment for hypoparathyroidism is based on oral calcium and active metabolites of vitamin  D / vitamin  D analogs and is aimed at the balance between optimal low-normal serum calcium concentrations and normocalciuria. Worsening hypercalciuria is often underestimated by specialists, although it can cause severe renal problems, such as nephrocalcinosis and neprolithiasis. Hypoparathyroidism is one of the few endocrine deficiencies for which replacement treatment with recombinant PTH is not widely used. Replacement therapy with recombinant human PTH is a  promising area, especially in severe clinical cases, refractory to conventional treatment.

About the authors

N. G. Mokrysheva

Endocrinology Research Center

Email: fake@neicon.ru

MD, PhD, Head of Parathyroid Glands Pathology Centre,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Russian Federation

A. K. Eremkina

Endocrinology Research Center

Author for correspondence.
Email: parathyroid.enc@gmail.com

MD, PhD, Research Fellow, Parathyroid Glands Pathology Centre,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Russian Federation

E. V. Kovaleva

Endocrinology Research Center

Email: fake@neicon.ru

Resident,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Russian Federation

References

  1. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391–403. doi: 10.1056/NEJMcp0803050.
  2. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317–37. doi: 10.1002/jbmr.483.
  3. Мокрышева НГ. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения. Дис. ... д-ра мед. наук. М.; 2011. 253 с.
  4. Мирная СС, Пигарова ЕА, Беляева АВ, Мокрышева НГ, Тюльпаков АН, Рожинская ЛЯ. Роль кальций-чувствительного рецептора в поддержании системы кальциевого гомеостаза. Остеопороз и остеопатии. 2010;(3):32–6.
  5. Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284–99. doi: 10.1210/jc.2015-3908.
  6. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12):2570–6. doi: 10.1002/jbmr.2004.
  7. Kakava K, Tournis S, Papadakis G, Karelas I, Stampouloglou P, Kassi E, Triantafillopoulos I, Villiotou V, Karatzas T. Postsurgical hypoparathyroidism: a systematic review. In Vivo. 2016;30(3):171–9.
  8. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101(4): 307–20. doi: 10.1002/bjs.9384.
  9. Sitges-Serra A, Ruiz S, Girvent M, Manjón H, Dueñas JP, Sancho JJ. Outcome of protracted hypoparathyroidism after total thyroidectomy. Br J Surg. 2010;97(11):1687–95. doi: 10.1002/bjs.7219.
  10. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343(25):1863–75. doi: 10.1056/NEJM200012213432508.
  11. Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, Sánchez-Velázquez P, Sitges-Serra A. Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surg. 2015;4(1):82–90. doi: 10.3978/j.issn.2227-684X.2014.12.04.
  12. Grodski S, Ser pell J. Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia. World J Surg. 2008;32(7):1367–73. doi: 10.1007/s00268-008-9545-5.
  13. Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015;102(4):359–67. doi: 10.1002/bjs.9676.
  14. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350(20):2068–79. doi: 10.1056/NEJMra030158.
  15. Orlova EM, Bukina AM, Kuznetsova ES, Kareva MA, Zakharova EU, Peterkova VA, Dedov II. Autoimmune polyglandular syndrome type 1 in Russian patients: clinical variants and autoimmune regulator mutations. Horm Res Paediatr. 2010;73(6):449–57. doi: 10.1159/000313585.
  16. Li Y, Song YH, Rais N, Connor E, Schatz D, Muir A, Maclaren N. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest. 1996;97(4):910–4. doi: 10.1172/JCI118513.
  17. Kemp EH, Habibullah M, Kluger N, Ranki A, Sandhu HK, Krohn KJ, Weetman AP. Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in Finnish APECED patients. J Clin Endocrinol Metab. 2014;99(3):1064–71. doi: 10.1210/jc.2013-3723.
  18. Kifor O, Moore FD Jr, Delaney M, Garber J, Hendy GN, Butters R, Gao P, Cantor TL, Kifor I, Brown EM, Wysolmerski J. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab. 2003;88(1):60–72. doi: 10.1210/jc.2002-020249.
  19. Alimohammadi M, Björklund P, Hallgren A, Pöntynen N, Szinnai G, Shikama N, Keller MP, Ekwall O, Kinkel SA, Husebye ES, Gustafsson J, Rorsman F, Peltonen L, Betterle C, Perheentupa J, Akerström G, Westin G, Scott HS, Holländer GA, Kämpe O. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med. 2008;358(10):1018–28. doi: 10.1056/NEJMoa0706487.
  20. Meloni A, Willcox N, Meager A, Atzeni M, Wolff AS, Husebye ES, Furcas M, Rosatelli MC, Cao A, Congia M. Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients. J Clin Endocrinol Metab. 2012;97(4):1114–24. doi: 10.1210/jc.2011-2461.
  21. Kifor O, McElduff A, LeBoff MS, Moore FD Jr, Butters R, Gao P, Cantor TL, Kifor I, Brown EM. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab. 2004;89(2):548–56. doi: 10.1210/jc.2003-031054.
  22. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455): 575–80. doi: 10.1038/366575a0.
  23. Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium. 2004;35(3):275–82.
  24. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet. 2002;360(9334):692–4. doi: 10.1016/S0140-6736(02)09842-2.
  25. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaître X, Paillard M, Planelles G, Déchaux M, Miller RT, Antignac C. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002;13(9):2259–66.
  26. Grigorieva IV, Thakker RV. Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. Ann N Y Acad Sci. 2011;1237:24–38. doi: 10.1111/j.1749-6632.2011.06221.x.
  27. Datta R, Waheed A, Shah GN, Sly WS. Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc Natl Acad Sci U S A. 2007;104(50):19989–94. doi: 10.1073/pnas.0708725104.
  28. Mannstadt M, Kronenberg HM. Parathyroid hormone gene: structure, evoluation, and regulation. In: Bilezikian JP, Marcus R, Levine MA, Claudio Marcocci C, Silverberg SJ, Potts JT. The parathyroids: basic and clinical concepts. 3rd edition. Elsevier; 2015. p. 590–3.
  29. Goldmuntz E. DiGeorge syndrome: new insights. Clin Perinatol. 2005;32(4):963–78, ix–x. doi: 10.1016/j.clp.2005.09.006.
  30. Thakker RV. Genetic developments in hypoparathyroidism. Lancet. 2001;357(9261): 974–6. doi: http://dx.doi.org/10.1016/S0140-6736(00)04254-9.
  31. Sanjad SA, Sakati NA, Abu-Osba YK, Kaddoura R, Milner RD. A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child. 1991;66(2):193–6.
  32. Maceluch JA, Niedziela M. The clinical diagnosis and molecular genetics of kearns-sayre syndrome: a complex mitochondrial encephalomyopathy. Pediatr Endocrinol Rev. 2006–2007;4(2):117–37.
  33. Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(10):3020–30. doi: 10.1210/jc.2011-1048.
  34. Bastepe M. The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol. 2008;626:27–40.
  35. Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002;11(4):403–10.
  36. Paunier L, Radde IC, Kooh SW, Conen PE, Fraser D. Primary hypomagnesemia with secondary hypocalcemia in an infant. Pediatrics. 1968;41(2):385–402.
  37. Okazaki R, Chikatsu N, Nakatsu M, Takeuchi Y, Ajima M, Miki J, Fujita T, Arai M, Totsuka Y, Tanaka K, Fukumoto S. A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J Clin Endocrinol Metab. 1999;84(1): 363–6. doi: 10.1210/jcem.84.1.5385.
  38. Потемкин ВВ, ред. Эндокринология: руководство для врачей. М.: Медицинское информационное агентство; 2013. 776 с.
  39. Schaaf M, Payne CA. Effect of diphenylhydantoin and phenobarbital on overt and latent tetany. N Engl J Med. 1966;274(22):1228–33. doi: 10.1056/NEJM196606022742203.
  40. Ballane GT, Sfeir JG, Dakik HA, Brown EM, ElHajj Fuleihan G. Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy. Eur J Endocrinol. 2012;166(6): 1113–20. doi: 10.1530/EJE-11-1094.
  41. Murros J, Luomanmäki K. A case of hypocalcemia, heart failure and exceptional repolarization disturbances. Acta Med Scand. 1980;208(1–2):133–6. doi: 10.1111/j.0954-6820.1980.tb01166.x.
  42. Rentoukas E, Lazaros G, Sotiriou S, Athanassiou M, Tsiachris D, Deftereos S, Stefanadis C. Extreme but not life-threatening QT interval prolongation? Take a closer look at the neck! J Electrocardiol. 2013;46(2):128–30. doi: 10.1016/j.jelectrocard.2012.10.007.
  43. Meena D, Prakash M, Gupta Y, Bhadada SK, Khandelwal N. Carotid, aorta and renal arteries intima-media thickness in patients with sporadic idiopathic hypoparathyroidism. Indian J Endocrinol Metab. 2015;19(2):262–6. doi: 10.4103/2230-8210.149320.
  44. Cohen GI, Aboufakher R, Bess R, Frank J, Othman M, Doan D, Mesiha N, Rosman HS, Szpunar S. Relationship between carotid disease on ultrasound and coronary disease on CT angiography. JACC Cardiovasc Imaging. 2013;6(11):1160–7. doi: 10.1016/j.jcmg.2013.06.007.
  45. Agarwal P, Prakash M, Singhal M, Bhadada SK, Gupta Y, Khandelwal N. To assess vascular calcification in the patients of hypoparathyroidism using multidetector computed tomography scan. Indian J Endocrinol Metab. 2015;19(6): 785–90. doi: 10.4103/2230-8210.167545.
  46. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. doi: 10.1136/bmj.d2040.
  47. Srirangarajan S, Satyanarayan A, Ravindra S, Thakur S. Dental manifestation of primary idiopathic hypoparathyroidism. J Indian Soc Periodontol. 2014;18(4):524–6. doi: 10.4103/0972-124X.138755.
  48. Minisola S, Dionisi S, Pacitti MT, Paglia F, Carnevale V, Scillitani A, Mazzaferro S, De GS, Pepe J, Derasmo E, Romagnoli E. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int. 2002;13(2):171–5.
  49. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018–24. doi: 10.1359/jbmr.080803.
  50. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507–14. doi: 10.1210/jc.2012-1808.
  51. Stack BC Jr, Bimston DN, Bodenner DL, Brett EM, Dralle H, Orloff LA, Pallota J, Snyder SK, Wong RJ, Randolph GW. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism – definitions and management. Endocr Pract. 2015;21(6):674–85. doi: 10.4158/EP14462.DSC.
  52. Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88(10):4655–8. doi: 10.1210/jc.2003-030470.
  53. Dempster D. Bone histomorphometry in hypoparathyroidism. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. New York: Springer; 2015. p. 287–96.
  54. Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E, Nickolas T, Stein E, Sliney J Jr, Silverberg SJ, Bilezikian JP, Müller R. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010;46(1):190–5. doi: 10.1016/j.bone.2009.09.020.
  55. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM; European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1–20. doi: 10.1530/EJE-15-0628.
  56. Society for Endocrinology. Emergency Endocrine Guidance – Acute hypocalcaemia (for use in adult patients), 2013 [Internet]. Available from: http://www.gloshospitals.nhs.uk/
  57. Diabetes/Diabetes%20Web%20Documents/Emergency%20Guidance%20Acute%20Hypocalcaemia%20in%20Adults.pdf.
  58. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012;58(2):158–62.
  59. Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215–22.
  60. Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4): 275–83. doi: 10.1016/S2213-8587(13)70106-2.
  61. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276(8):631–6. doi: 10.1001/jama.1996.03540080053029.
  62. Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83(10):3480–6. doi: 10.1210/jcem.83.10.5185.
  63. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88(9):4214–20. doi: 10.1210/jc.2002-021736.
  64. Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21(11):1927–34. doi: 10.1007/s00198-009-1149-x.
  65. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. doi: 10.1056/NEJM200105103441904.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Mokrysheva N.G., Eremkina A.K., Kovaleva E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies